{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03532399",
            "orgStudyIdInfo": {
                "id": "IRB-P00027930"
            },
            "organization": {
                "fullName": "Boston Children's Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation",
            "officialTitle": "Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation",
            "therapeuticArea": [
                "Other"
            ],
            "study": "pharmacokinetics-of-bivalirudin-for-pediatric-anticoagulation"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-07-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-04-17",
            "studyFirstSubmitQcDate": "2018-05-21",
            "studyFirstPostDateStruct": {
                "date": "2018-05-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Katherine Zaleski",
                "investigatorTitle": "Instructor in Anaesthesia",
                "investigatorAffiliation": "Boston Children's Hospital"
            },
            "leadSponsor": {
                "name": "Boston Children's Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study will measure plasma concentrations of bivalirudin in pediatric patients undergoing cardiac catheterization, cardiac surgical procedures utilizing cardiopulmonary bypass (CPB), or extracorporeal support with ECMO, ventricular support devices (VAD) or lung-assist devices (LAD). The aim is to understand the pharmacokinetics of bivalirudin in these settings."
        },
        "conditionsModule": {
            "conditions": [
                "Drug Effect"
            ],
            "keywords": [
                "Bivalirudin"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_ONLY",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pediatric Cardiac Catheterization",
                    "interventionNames": [
                        "Drug: Bivalirudin"
                    ]
                },
                {
                    "label": "Pediatric Cardiac Surgery",
                    "interventionNames": [
                        "Drug: Bivalirudin"
                    ]
                },
                {
                    "label": "Pediatric Extracorporeal Life Support (ECLS)",
                    "interventionNames": [
                        "Drug: Bivalirudin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bivalirudin",
                    "description": "CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \\> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.\n\nCardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.\n\nECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider.",
                    "armGroupLabels": [
                        "Pediatric Cardiac Catheterization",
                        "Pediatric Cardiac Surgery",
                        "Pediatric Extracorporeal Life Support (ECLS)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Plasma Bivalirudin Concentration",
                    "description": "The primary end-point will be the plasma bivalirudin concentration (nanogram/mL) measured at multiple set time-points throughout the administration of bivalirudin in order to delineate the pharmacokinetic profile in the pediatric population.",
                    "timeFrame": "Throughout the duration of treatment with bivalirudin and for one hour after the infusion is stopped. To be specific: 1. In CPB and cath lab cases arm: average 6 hours. 2. In ECLS arm: average 10 days."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "thrombotic complications",
                    "description": "arterial, venous, and/or CPB/ECMO/VAD thrombosis; embolic stroke",
                    "timeFrame": "Data will be assessed continuously in the procedural groups throughout the duration of the infusion and then continued weekly throughout the length of the hospital stay up to one year from enrollment."
                },
                {
                    "measure": "bleeding in excess of expectations for a given procedure or ECLS modality",
                    "timeFrame": "Data will be assessed continuously in the procedural groups throughout the duration of the infusion and then continued weekly throughout the length of the hospital stay up to one year from enrollment."
                },
                {
                    "measure": "mortality",
                    "timeFrame": "Data will be assessed continuously in the procedural groups throughout the duration of the infusion and then continued weekly throughout the length of the hospital stay or until death up to one year from enrollment."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* pediatric patient (age less than 18 years)\n* weight \\> 3kg\n* scheduled to undergo 1) cardiac catheterization, 2)cardiac surgical procedure utilizing CPB, and/or 3) the institution of extracorporeal support\n* must already require the administration of bivalirudin as part of their treatment plan\n\nExclusion Criteria:\n\n* Age equal to or greater than 18 years,\n* weight less than 3kg\n* end-stage renal failure requiring renal replacement therapy.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ],
            "studyPopulation": "Pediatric (age less than 18 years and more than 3kg) patients who present to Boston Children's Hospital (BCH) for cardiac catheterization, a cardiac surgical procedure utilizing CPB, or the institution of extracorporeal support and who require the administration of bivalirudin as part of their treatment plan will be included.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Zaleski L Zaleski, MD",
                    "role": "CONTACT",
                    "phone": "6173557737",
                    "email": "katherine.zaleski@childrens.harvard.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Boston Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02116",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000074619",
                    "term": "Bivalirudin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000991",
                    "term": "Antithrombins"
                },
                {
                    "id": "D000015842",
                    "term": "Serine Proteinase Inhibitors"
                },
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000925",
                    "term": "Anticoagulants"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M341693",
                    "name": "Bivalirudin",
                    "asFound": "Rise",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4307",
                    "name": "Antithrombins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4306",
                    "name": "Antithrombin III",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M18391",
                    "name": "Serine Proteinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4244",
                    "name": "Anticoagulants",
                    "relevance": "LOW"
                },
                {
                    "id": "T18",
                    "name": "Serine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnCoag",
                    "name": "Anticoagulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}